Scribe Therapeutics deepens in vivo CRISPR validation with second Eli Lilly collaboration milestone
Scribe Therapeutics hits a second in vivo CRISPR milestone with Eli Lilly. Explore what this changes for gene editing platforms and future therapies.
What Lilly’s Orna Therapeutics deal means for immune reset strategies
Eli Lilly and Company has entered into a definitive agreement to acquire Orna Therapeutics, Inc., gaining access to the biotechnology firm’s circular RNA platform and its clinical trial ready in vivo CAR-T candidate ORN-252 targeting CD19 for B cell driven autoimmune diseases. The deal, valued at up to 2.4 billion dollars in cash including milestone […]